Cefotiam (CAS 61622-34-2)

Cefotiam, a second-generation cephalosporin antibiotic, has garnered considerable attention in scientific research due to its potent antimicrobial properties and diverse applications in the field of microbiology. The mechanism of action of cefotiam involves the inhibition of bacterial cell wall synthesis by binding irreversibly to penicillin-binding proteins (PBPs), notably PBP-3, thereby disrupting peptidoglycan cross-linking and leading to bacterial cell lysis. This mechanism confers cefotiam with broad-spectrum bactericidal activity against various Gram-positive and Gram-negative bacterial pathogens, including Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pneumoniae. Research endeavors have extensively investigated the pharmacokinetic properties of cefotiam, elucidating its absorption, distribution, metabolism, and excretion pathways, to optimize dosing regimens and enhance efficacy. Furthermore, studies have explored the potential synergistic interactions of cefotiam with other antimicrobial agents to combat antibiotic resistance and improve treatment outcomes. Additionally, cefotiam has been utilized as a valuable tool in microbiological research to investigate bacterial resistance mechanisms, explain structure-activity relationships, and develop novel antimicrobial compounds. Ongoing research efforts continue to explore the pharmacological and microbiological aspects of cefotiam, aiming to expand its utility in combating infectious diseases and addressing emerging antibiotic resistance challenges.